2024 half year results innovation progress 2024 half year results innovation progress First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
Two new claims for Nexgard range in EU and Australia Two new claims for Nexgard range in EU and Australia Boehringer Ingelheim expands the label claims of its NexGard® brands for the treatment of two severe skin diseases in dogs in the EU and in Australia.
Breakthrough Designation granted in US and China Breakthrough Designation granted in US and China SPEVIGO® granted Breakthrough Therapy Designation in the U.S. for the prevention of generalized pustular psoriasis flares
Spesolimab prevents GPP flares Spesolimab prevents GPP flares Spesolimab prevents generalized pustular psoriasis flares in EFFISAYIL™ 2 trial
Innovation in medicinal chemistry Innovation in medicinal chemistry Darryl McConnell, Research Site Head, Austria and Jürgen Mack, Medicinal Chemistry, explain how we are working to unlock unsolved diseases
Spesolimab meets key endpoint for GPP flare prevention Spesolimab meets key endpoint for GPP flare prevention Spesolimab meets primary and key secondary endpoint for prevention of generalized pustular psoriasis flares
EASi-HF™ Phase III trial in patients with HFpEF EASi-HF™ Phase III trial in patients with HFpEF Boehringer Ingelheim's Sandy Sommer on the global urgency for innovative heart failure care and the significance of the clinical trial for patients with HFpEF worldwide.
EASi-KIDNEY™ Phase III trial for people with CKD EASi-KIDNEY™ Phase III trial for people with CKD Boehringer Ingelheim's Sandy Sommer on how treatment innovations in CKD can also improve care for connected conditions, including heart failure.